LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListBoston Scientific Corp.

Boston Scientific Corp.

Closed

Sector Healthcare

68.94 0.36

Overview

Share price change

24h

Current

Min

68.53

Max

69.2

Key metrics

By Trading Economics

Income

-1M

504M

Sales

198M

3.7B

P/E

Sector Avg

70.871

23.904

EPS

0.55

Profit margin

13.53

Employees

48,000

EBITDA

87M

1B

Recommendations

By TipRanks

Rating Consensus

StrongBuy

12 Months Forecast

+3.68 upside

Dividends

By Dow Jones

Next earnings

24 Apr 2024

Market Stats

By TradingEconomics

Market Cap

2B

101B

Previous open

68.58

Previous close

68.94

News Sentiment

By Acuity

52%

48%

210 / 274 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Boston Scientific Corp. chart

Related News

4 Apr 2024, 12:00 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information

31 Jan 2024, 12:09 UTC

Earnings

Boston Scientific Posts 4Q Net, Sales Growth, Sees More Growth in '24

8 Jan 2024, 16:21 UTC

Major Market Movers
Acquisitions, Mergers, TakeOvers

Axonics Shares Climb 20% After Acquisition by Boston Scientific

8 Jan 2024, 12:26 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific To Acquire Axonics For About $3.7 Billion

4 Apr 2024, 11:25 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific Now Sees Mereger Closing in 2H of 2024 >BSX

4 Apr 2024, 11:24 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific, Axionics Expect to Promptly Respond to Second Request >BSX

4 Apr 2024, 11:24 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific, Axonics Receive Request for Additional Info From FTC Regarding Merger >BSX

31 Jan 2024, 14:19 UTC

Earnings

Boston Scientific Surges On Its 'Impressive' First-Quarter Guidance -- IBD

31 Jan 2024, 12:59 UTC

Earnings

Stryker, Boston Scientific Score Earnings Beats, Extend Breakouts -- IBD

31 Jan 2024, 11:33 UTC

Earnings

Boston Scientific Sees 2024 Sales Up 8.5%-9.5%, Organic Sales Up 8%-9% >BSX

31 Jan 2024, 11:32 UTC

Earnings

Boston Scientific Sees 1Q Sales Up 7.5%-9.5%, Organic Sales Up 7%-9% >BSX

31 Jan 2024, 11:31 UTC

Earnings

Boston Scientific 4Q Organic Sales Rose 13.6% >BSX

31 Jan 2024, 11:31 UTC

Earnings

Boston Scientific Sees 2024 Adj EPS $2.23-Adj EPS $2.27 >BSX

31 Jan 2024, 11:31 UTC

Earnings

Boston Scientific Sees 2024 EPS $1.38-EPS $1.42 >BSX

31 Jan 2024, 11:30 UTC

Earnings

Boston Scientific Sees 1Q Adj EPS 50c-Adj EPS 52c >BSX

31 Jan 2024, 11:30 UTC

Earnings

Boston Scientific Sees 1Q EPS 29c-EPS 31c >BSX

31 Jan 2024, 11:30 UTC

Earnings

Boston Scientific 4Q Adj EPS 55c >BSX

31 Jan 2024, 11:30 UTC

Earnings

Boston Scientific 4Q EPS 34c >BSX

31 Jan 2024, 11:30 UTC

Earnings

Boston Scientific 4Q Sales $3.725B >BSX

8 Jan 2024, 13:18 UTC

Acquisitions, Mergers, TakeOvers

Axonics Stock Soars. It's Being Acquired By Boston Scientific In $3.7 Billion Deal. -- Barrons.com

8 Jan 2024, 12:12 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific: Acquisition Impact to GAAP EPS Expected to Be Less Accretive, or More Dilutive, Due to Amortization Expense and Acquisition-Related Net Charges >BSX

8 Jan 2024, 12:12 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific Sees Acquisition Impact to Adj EPS Immaterial in 2024 and Accretive Thereafter >BSX

8 Jan 2024, 12:11 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific: Axonics' Rev Growth Profile Is Anticipated to Be Highly Accretive to BSX Urology Business in 2024 >BSX

8 Jan 2024, 12:11 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific: Axonics Expects to Deliver Net Rev of About $366 M in 2023 >BSX

8 Jan 2024, 12:11 UTC

Top News
Acquisitions, Mergers, TakeOvers

Boston Scientific To Acquire Axonics For About $3.7 Bln

8 Jan 2024, 12:10 UTC

Acquisitions, Mergers, TakeOvers

Axonic's Stock Soars After Cash Buyout Deal With Boston Scientific Valued At $3.7 Billion -- MarketWatch

8 Jan 2024, 12:02 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific: Deal Reflects Equity Value of About $3.7B and Enterprise Value of About $3.4B

8 Jan 2024, 12:02 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific: Acquisition to Expand Urology Portfolio With Differentiated Technologies to Treat Urinary and Bowel Dysfunction >BSX

8 Jan 2024, 12:02 UTC

Acquisitions, Mergers, TakeOvers

Boston Scientific to Buy Axonics for $71 in Cash Per Share >BSX AXNX

8 Jan 2024, 12:01 UTC

Acquisitions, Mergers, TakeOvers

Axonics to Be Acquired for $71/Share; Closed Friday at $57.57 >BSX AXNX

Peer Comparison

Price change

Boston Scientific Corp. forecast

Price Target

By TipRanks

3.68% upside

12 Months Forecast

Average 71.37 USD  3.68%

High 81 USD

Low 60 USD

Based on 20 Wall Street analysts offering 12 month price targets for Boston Scientific Corp. - Dist in the last 3 months.

Rating Consensus

By TipRanks

StrongBuy

20 ratings

17

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

67.9 / 68.915 Support&Resistance

Short Team

Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

210 / 274 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Boston Scientific Corp.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by businesses such Interventional Cardiology, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health, Neuromodulation and Specialty Pharmaceuticals. It operates in three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. MedSurg consists of Endoscopy and Urology and Pelvic Health businesses. Rhythm segment consists of Cardiac Rhythm Management, Electrophysiology and Neuromodulation businesses. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.